Evaluation of mass spectrometry of urinary proteins and peptides as biomarkers for cats at risk of developing azotemia

Rosanne E. Jepson Department of Veterinary Clinical Sciences, Royal Veterinary College, NW1 0TU, London, England.

Search for other papers by Rosanne E. Jepson in
Current site
Google Scholar
PubMed
Close
 BVSc, MVetMed, PhD
,
Gary R. Coulton St George's Medical Biomics Centre, St George's University of London, SW17 0RE, London, England.

Search for other papers by Gary R. Coulton in
Current site
Google Scholar
PubMed
Close
 PhD
,
Matthew L. Cowan St George's Medical Biomics Centre, St George's University of London, SW17 0RE, London, England.

Search for other papers by Matthew L. Cowan in
Current site
Google Scholar
PubMed
Close
 BSc
,
Peter Markwell WALTHAM, a Division of Mars Inc, LE14 4RT, Melton Mowbray, England.

Search for other papers by Peter Markwell in
Current site
Google Scholar
PubMed
Close
 BVetMed
,
Harriet M. Syme Department of Veterinary Clinical Sciences, Royal Veterinary College, NW1 0TU, London, England.

Search for other papers by Harriet M. Syme in
Current site
Google Scholar
PubMed
Close
 BVetMed, PhD
, and
Jonathan Elliott Department of Veterinary Basic Sciences, Royal Veterinary College, NW1 0TU, London, England.

Search for other papers by Jonathan Elliott in
Current site
Google Scholar
PubMed
Close
 VetMB, PhD

Abstract

Objective—To evaluate proteomic delineation of feline urine by mass spectrometry as a method for identifying biomarkers in cats at risk of developing azotemia.

Samples—Urine samples from geriatric cats (> 9 years old) with chronic kidney disease and nonazotemic cats that either remained nonazotemic (n = 10) or developed azotemia (10) within 1 year.

Procedures—Optimization studies with pooled urine were performed to facilitate the use of surface enhanced laser desorption-ionization time-of-flight mass spectrometry (SELDI-TOF-MS) for analysis of the urinary proteome of cats. Urine samples from nonazotemic cats at entry to the study were analyzed via SELDI-TOF-MS with weak cation exchange and strong anion exchange arrays. Spectral data were compared to identify biomarkers for development of azotemia.

Results—Low protein concentration in feline urine precluded direct application to array surfaces, and a buffer exchange and concentration step was required prior to SELDI-TOF-MS analysis. Three preparation conditions by use of weak cation and strong anion exchange arrays were selected on the basis of optimization studies for detection of biomarkers. Eight potential biomarkers with an m/z of 2,822, 9,886, 10,033, 10,151, 10,234, 11,653, 4,421, and 9,505 were delineated.

Conclusions and Clinical Relevance—SELDI-TOF-MS can be used to detect urinary low-molecular weight peptides and proteins that may represent biomarkers for early detection of renal damage. Further study is required to purify and identify potential biomarkers before their use in a clinical setting.

Abstract

Objective—To evaluate proteomic delineation of feline urine by mass spectrometry as a method for identifying biomarkers in cats at risk of developing azotemia.

Samples—Urine samples from geriatric cats (> 9 years old) with chronic kidney disease and nonazotemic cats that either remained nonazotemic (n = 10) or developed azotemia (10) within 1 year.

Procedures—Optimization studies with pooled urine were performed to facilitate the use of surface enhanced laser desorption-ionization time-of-flight mass spectrometry (SELDI-TOF-MS) for analysis of the urinary proteome of cats. Urine samples from nonazotemic cats at entry to the study were analyzed via SELDI-TOF-MS with weak cation exchange and strong anion exchange arrays. Spectral data were compared to identify biomarkers for development of azotemia.

Results—Low protein concentration in feline urine precluded direct application to array surfaces, and a buffer exchange and concentration step was required prior to SELDI-TOF-MS analysis. Three preparation conditions by use of weak cation and strong anion exchange arrays were selected on the basis of optimization studies for detection of biomarkers. Eight potential biomarkers with an m/z of 2,822, 9,886, 10,033, 10,151, 10,234, 11,653, 4,421, and 9,505 were delineated.

Conclusions and Clinical Relevance—SELDI-TOF-MS can be used to detect urinary low-molecular weight peptides and proteins that may represent biomarkers for early detection of renal damage. Further study is required to purify and identify potential biomarkers before their use in a clinical setting.

All Time Past Year Past 30 Days
Abstract Views 200 0 0
Full Text Views 1888 1652 223
PDF Downloads 212 108 10
Advertisement